Interstim Continence Control Therapy
Company: Medtronic
Approval Status: Approved September 1997
Treatment for: urinary incontinence
Areas: Nephrology/Urology
General Information
Other Useful Resources
Interstim Continence Control Therapy has been approved by the Food and Drug Administration (FDA). This is the first implantable treatment ever to use electrical stimulation of the sacral nerves to manage urinary urge incontinence. Depending on the patient, Interstim Continence Control Therapy can be used instead of, or in conjunction with, more conservative therapies, such as physical therapy, drug therapy and biofeedback.
The FDA drug information shown here is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.
